| Title |
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial
|
|---|---|
| Published in |
Trials, August 2020
|
| DOI | 10.1186/s13063-020-04632-4 |
| Pubmed ID | |
| Authors |
Miguel Rodríguez-Rubio, Juan Carlos Figueira, Darío Acuña-Castroviejo, Alberto M. Borobia, Germaine Escames, Pedro de la Oliva |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 21% |
| Brazil | 1 | 7% |
| Uruguay | 1 | 7% |
| United Kingdom | 1 | 7% |
| India | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 6 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 43% |
| Scientists | 5 | 36% |
| Practitioners (doctors, other healthcare professionals) | 2 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 300 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 300 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 41 | 14% |
| Researcher | 34 | 11% |
| Student > Master | 28 | 9% |
| Other | 20 | 7% |
| Student > Ph. D. Student | 13 | 4% |
| Other | 52 | 17% |
| Unknown | 112 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 81 | 27% |
| Nursing and Health Professions | 32 | 11% |
| Biochemistry, Genetics and Molecular Biology | 10 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 3% |
| Psychology | 8 | 3% |
| Other | 37 | 12% |
| Unknown | 122 | 41% |